Finerenone (Kerendia®). HTA ID: 22012
Finerenone (Kerendia®) is indicated for the treatment of chronic kidney disease (stage 3 and 4 with albuminuria) associated with type 2 diabetes in adults.
| NCPE Assessment Process | Complete |
| Rapid review commissioned | 21/02/2022 |
| Rapid review completed | 15/03/2022 |
| Rapid Review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of finerenone compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by the HSE | 01/04/2022 |
| Pre-submission consultation with Applicant | 24/05/2022 |
| Current Status | Awaiting HTA submission from Applicant |